Abnormal bone quality in cartilage oligomeric matrix protein and matrilin 3 double-deficient mice caused by increased tissue inhibitor of metalloproteinases 3 deposition and delayed aggrecan degradation

Arthritis and Rheumatism

Volumn 64, Issue 8, 2012, Pages 2644-2654

  Groma, Gergely ^a   Xin, Wei ^a   Grskovic, Ivan ^a   Niehoff, Anja ^a   Brachvogel, Bent ^a   Paulsson, Mats ^a   Zaucke, Frank ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AGGRECAN; AGGRECANASE 1; AGGRECANASE 2; CARTILAGE OLIGOMERIC MATRIX PROTEIN; COLLAGEN TYPE 2; COLLAGENASE 3; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRILIN 3; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 3;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY HEIGHT; BONE DENSITY; BONE DEVELOPMENT; BONE REMODELING; CONTROLLED STUDY; ENCHONDRAL OSSIFICATION; FEMUR; IMMUNOREACTIVITY; LONG BONE; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; UPREGULATION;

AGGRECANS; AGING; ANIMALS; ANIMALS, NEWBORN; BONE AND BONES; BONE DENSITY; EXTRACELLULAR MATRIX PROTEINS; GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MODELS, ANIMAL; PHENOTYPE; TISSUE INHIBITOR OF METALLOPROTEINASE-3;

EID: 84864451392     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.34435     Document Type: Article

References (49)

1. Klatt AR, Becker AK, Neacsu CD, Paulsson M, Wagener R,. The matrilins: modulators of extracellular matrix assembly. Int J Biochem Cell Biol 2011; 43: 320-30.
2. Wagener R, Ehlen HW, Ko YP, Kobbe B, Mann HH, Sengle G, et al. The matrilins-adaptor proteins in the extracellular matrix. FEBS Lett 2005; 579: 3323-9.
3. Mann HH, Ozbek S, Engel J, Paulsson M, Wagener R,. Interactions between the cartilage oligomeric matrix protein and matrilins: implications for matrix assembly and the pathogenesis of chondrodysplasias. J Biol Chem 2004; 279: 25294-8.
4. Budde B, Blumbach K, Ylostalo J, Zaucke F, Ehlen HW, Wagener R, et al. Altered integration of matrilin-3 into cartilage extracellular matrix in the absence of collagen IX. Mol Cell Biol 2005; 25: 10465-78.
5. Huang XM, Birk DE, Goetinck PF,. Mice lacking matrilin-1 (cartilage matrix protein) have alterations in type II collagen fibrillogenesis and fibril organization. Dev Dyn 1999; 216: 434-41.
6. Nicolae C, Ko YP, Miosge N, Niehoff A, Studer D, Enggist L, et al. Abnormal collagen fibrils in cartilage of matrilin-1/matrilin-3-deficient mice. J Biol Chem 2007; 282: 22163-75.
7. Wiberg C, Klatt AR, Wagener R, Paulsson M, Bateman JF, Heinegard D, et al. Complexes of matrilin-1 and biglycan or decorin connect collagen VI microfibrils to both collagen II and aggrecan. J Biol Chem 2003; 278: 37698-704.
8. Hedbom E, Antonsson P, Hjerpe A, Aeschlimann D, Paulsson M, Rosa-Pimentel E, et al. Cartilage matrix proteins: an acidic oligomeric protein (COMP) detected only in cartilage. J Biol Chem 1992; 267: 6132-6.
9. Rosenberg K, Olsson H, Morgelin M, Heinegard D,. Cartilage oligomeric matrix protein shows high affinity zinc-dependent interaction with triple helical collagen. J Biol Chem 1998; 273: 20397-403.
10. Halasz K, Kassner A, Morgelin M, Heinegard D,. COMP acts as a catalyst in collagen fibrillogenesis. J Biol Chem 2007; 282: 31166-73.
11. Holden P, Meadows RS, Chapman KL, Grant ME, Kadler KE, Briggs MD,. Cartilage oligomeric matrix protein interacts with type IX collagen, and disruptions to these interactions identify a pathogenetic mechanism in a bone dysplasia family. J Biol Chem 2001; 276: 6046-55.
12. 587→Arg) in the C-terminal, collagen-binding domain of cartilage oligomeric matrix protein (COMP). Biochem J 2004; 377: 479-87.
13. Thur J, Rosenberg K, Nitsche DP, Pihlajamaa T, Ala-Kokko L, Heinegard D, et al. Mutations in cartilage oligomeric matrix protein causing pseudoachondroplasia and multiple epiphyseal dysplasia affect binding of calcium and collagen I, II, and IX. J Biol Chem 2001; 276: 6083-92.
14. Chen FH, Herndon ME, Patel N, Hecht JT, Tuan RS, Lawler J,. Interaction of cartilage oligomeric matrix protein/thrombospondin 5 with aggrecan. J Biol Chem 2007; 282: 24591-8.
15. Briggs MD, Chapman KL,. Pseudoachondroplasia and multiple epiphyseal dysplasia: mutation review, molecular interactions, and genotype to phenotype correlations. Hum Mutat 2002; 19: 465-78.
16. Briggs MD, Hoffman SM, King LM, Olsen AS, Mohrenweiser H, Leroy JG, et al. Pseudoachondroplasia and multiple epiphyseal dysplasia due to mutations in the cartilage oligomeric matrix protein gene. Nat Genet 1995; 10: 330-6.
17. Chapman KL, Mortier GR, Chapman K, Loughlin J, Grant ME, Briggs MD,. Mutations in the region encoding the von Willebrand factor A domain of matrilin-3 are associated with multiple epiphyseal dysplasia. Nat Genet 2001; 28: 393-6.
18. Svensson L, Aszodi A, Heinegard D, Hunziker EB, Reinholt FP, Fassler R, et al. Cartilage oligomeric matrix protein-deficient mice have normal skeletal development. Mol Cell Biol 2002; 22: 4366-71.
19. Ko YP, Kobbe B, Nicolae C, Miosge N, Paulsson M, Wagener R, et al. Matrilin-3 is dispensable for mouse skeletal growth and development. Mol Cell Biol 2004; 24: 1691-9.
20. Van der Weyden L, Wei L, Luo JM, Yang X, Birk DE, Adams DJ, et al. Functional knockout of the matrilin-3 gene causes premature chondrocyte maturation to hypertrophy and increases bone mineral density and osteoarthritis. Am J Pathol 2006; 169: 515-27.
21. Blumbach K, Niehoff A, Paulsson M, Zaucke F,. Ablation of collagen IX and COMP disrupts epiphyseal cartilage architecture. Matrix Biol 2008; 27: 306-18.
22. Hagg R, Hedbom E, Mollers U, Aszodi A, Fassler R, Bruckner P,. Absence of the α1(IX) chain leads to a functional knock-out of the entire collagen IX protein in mice. J Biol Chem 1997; 272: 20650-4.
23. Laemmli UK,. Cleavage of structural proteins during assembly of the head of bacteriophage T4. Nature 1970; 227: 680-5.
24. Di Cesare PE, Fang C, Leslie MP, Tulli H, Perris R, Carlson CS,. Expression of cartilage oligomeric matrix protein (COMP) by embryonic and adult osteoblasts. J Orthop Res 2000; 18: 713-20.
25. Klatt AR, Nitsche DP, Kobbe B, Macht M, Paulsson M, Wagener R,. Molecular structure, processing, and tissue distribution of matrilin-4. J Biol Chem 2001; 276: 17267-75.
26. Singer II, Kawka DW, Bayne EK, Donatelli SA, Weidner JR, Williams HR, et al. VDIPEN, a metalloproteinase-generated neoepitope, is induced and immunolocalized in articular cartilage during inflammatory arthritis. J Clin Invest 1995; 95: 2178-86.
27. Aszodi A, Chan D, Hunziker E, Bateman JF, Fassler R,. Collagen II is essential for the removal of the notochord and the formation of intervertebral discs. J Cell Biol 1998; 143: 1399-412.
28. Yu WH, Yu SS, Meng Q, Brew K, Woessner JF,. TIMP-3 binds to sulfated glycosaminoglycans of the extracellular matrix. J Biol Chem 2000; 275: 31226-32.
29. Klenotic PA, Munier FL, Marmorstein LY, Anand-Apte B,. Tissue inhibitor of metalloproteinases-3 (TIMP-3) is a binding partner of epithelial growth factor-containing fibulin-like extracellular matrix protein 1 (EFEMP1): implications for macular degeneration. J Biol Chem 2004; 279: 30469-73.
30. Leighton MP, Nundlall S, Starborg T, Meadows RS, Suleman F, Knowles L, et al. Decreased chondrocyte proliferation and dysregulated apoptosis in the cartilage growth plate are key features of a murine model of epiphyseal dysplasia caused by a matn3 mutation. Hum Mol Genet 2007; 16: 1728-41.
31. Pirog KA, Jaka O, Katakura Y, Meadows RS, Kadler KE, Boot-Handford RP, et al. A mouse model offers novel insights into the myopathy and tendinopathy often associated with pseudoachondroplasia and multiple epiphyseal dysplasia. Hum Mol Genet 2010; 19: 52-64.
32. Nakagawa M, Kaneda T, Arakawa T, Morita S, Sato T, Yomada T, et al. Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts. FEBS Lett 2000; 473: 161-4.
33. Zelzer E, Olsen BR,. Multiple roles of vascular endothelial growth factor (VEGF) in skeletal development, growth, and repair. Curr Top Dev Biol 2005; 65: 169-87.
34. Rajpar MH, McDermott B, Kung L, Eardley R, Knowles L, Heeran M, et al. Targeted induction of endoplasmic reticulum stress induces cartilage pathology. PLoS Genet 2009; 5: e100069.
35. Caterson B, Flannery CR, Hughes CE, Little CB,. Mechanisms of proteoglycan metabolism that lead to cartilage destruction in the pathogenesis of arthritis. Drugs Today (Barc) 1999; 35: 397-402.
36. Mort JS, Billington CJ,. Articular cartilage and changes in arthritis: matrix degradation. Arthritis Res 2001; 3: 337-41.
37. Huang K, Wu LD,. Aggrecanase and aggrecan degradation in osteoarthritis: a review. J Int Med Res 2008; 36: 1149-60.
38. Nagase H, Kashiwagi M,. Aggrecanases and cartilage matrix degradation. Arthritis Res Ther 2003; 5: 94-103.
39. Fosang AJ, Last K, Knauper V, Murphy G, Neame PJ,. Degradation of cartilage aggrecan by collagenase-3 (MMP-13). FEBS Lett 1996; 380: 17-20.
40. Fosang AJ, Last K, Knauper V, Neame PJ, Murphy G, Hardingham TE, et al. Fibroblast and neutrophil collagenases cleave at 2 sites in the cartilage aggrecan interglobular domain. Biochem J 1993; 295: 273-6.
41. Nagase H, Woessner JF,. Matrix metalloproteinases. J Biol Chem 1999; 274: 21491-4.
42. Varghese S,. Matrix metalloproteinases and their inhibitors in bone: an overview of regulation and functions. Front Biosci 2006; 11: 2949-66.
43. -/- mice. Arthritis Rheum 2007; 56: 905-9.
44. -/- mice. Oncogene 2006; 25: 6489-96.
45. Paulsson M, Heinegard D,. Matrix proteins bound to associatively prepared proteoglycans from bovine cartilage. Biochem J 1979; 183: 539-45.
46. Hauser N, Paulsson M, Heinegard D, Morgelin M,. Interaction of cartilage matrix protein with aggrecan: increased covalent cross-linking with tissue maturation. J Biol Chem 1996; 271: 32247-52.
47. Little CB, Barai A, Burkhardt D, Smith SM, Fosang AJ, Werb Z, et al. Matrix metalloproteinase 13-deficient mice are resistant to osteoarthritic cartilage erosion but not chondrocyte hypertrophy or osteophyte development. Arthritis Rheum 2009; 60: 3723-33.
48. Stickens D, Behonick DJ, Ortega N, Heyer B, Hartenstein B, Yu Y, et al. Altered endochondral bone development in matrix metalloproteinase 13-deficient mice. Development 2004; 131: 5883-95.
49. Takaishi H, Kimura T, Dalal S, Okada Y, D'Armiento J,. Joint diseases and matrix metalloproteinases: a role for MMP-13. Curr Pharm Biotechnol 2008; 9: 47-54.